Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

596

Participants

Timeline

Start Date

December 3, 2018

Primary Completion Date

October 30, 2020

Study Completion Date

April 30, 2022

Conditions

Advanced Esophageal Cancer

Interventions

DRUG

SHR-1210

SHR-1210 200mg

DRUG

Placebo

DRUG

paclitaxel

paclitaxel 175mg/m2

DRUG

cisplatin

cisplatin 75mg/m2

Trial Locations (1)

Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03691090 - Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer | Biotech Hunter | Biotech Hunter